SanBio Co (TSE:4592) Debt-to-Asset : 0.13 (As of Jan. 2024)

View and export this data going back to 2015. Start your Free Trial

What is SanBio Co Debt-to-Asset?

SanBio Co's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Jan. 2024 was 円268.00 Mil. SanBio Co's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Jan. 2024 was 円397.00 Mil. SanBio Co's Long-Term Debt & Capital Lease ObligationTotal Assets for the quarter that ended in Jan. 2024 was 円5,047.29 Mil. SanBio Co's debt to asset for the quarter that ended in Jan. 2024 was 0.13.

SanBio Co Debt-to-Asset Historical Data

The historical data trend for SanBio Co's Debt-to-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

SanBio Co Debt-to-Asset Chart

SanBio Co Annual Data

Trend

Jan15

Jan16

Jan17

Jan18

Jan19

Jan20

Jan21

Jan22

Jan23

Jan24

Debt-to-Asset

Get a 7-Day Free Trial

0.26

0.30

0.46

0.13

SanBio Co Quarterly Data
	Apr19	Jul19	Oct19	Jan20	Apr20	Jul20	Oct20	Jan21	Apr21	Jul21	Oct21	Jan22	Apr22	Jul22	Oct22	Jan23	Apr23	Jul23	Oct23	Jan24
Debt-to-Asset	Get a 7-Day Free Trial															0.13	0.15	0.16	0.17	0.13

Competitive Comparison of SanBio Co's Debt-to-Asset

For the Biotechnology subindustry, SanBio Co's Debt-to-Asset, along with its competitors' market caps and Debt-to-Asset data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

SanBio Co's Debt-to-Asset Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, SanBio Co's Debt-to-Asset distribution charts can be found below:

* The bar in red indicates where SanBio Co's Debt-to-Asset falls into.

SanBio Co Debt-to-Asset Calculation

Debt to Asset measures the financial leverage a company has.

SanBio Co's Debt-to-Asset for the fiscal year that ended in Jan. 2024 is calculated as

Debt-to-Asset	=	Total Debt			/	Total Assets
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Assets
	=	(268	+	397)	/	5047.291
	=	0.13

SanBio Co's Debt-to-Asset for the quarter that ended in Jan. 2024 is calculated as

Debt-to-Asset	=	Total Debt			/	Total Assets
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Assets
	=	(268	+	397)	/	5047.291
	=	0.13

SanBio Co (TSE:4592) Debt-to-Asset Explanation

In the calculation of Debt-to-Asset, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Assets.

SanBio Co Debt-to-Asset Related Terms

Thank you for viewing the detailed overview of SanBio Co's Debt-to-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.

SanBio Co (TSE:4592) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » SanBio Co Ltd (TSE:4592) » Definitions » Debt-to-Asset

Comparable Companies

Traded in Other Exchanges

SNBIF:USA

Address

8-1 Street Luke Tower 32nd Floor, Akashi-cho, Chuo-ku, Tokyo, JPN, 104-0044

Website

https://www.sanbio.com

SanBio Co Ltd is engaged in the research and development of regenerative cells drugs. The company has three types of drugs under development, including nerve regeneration cell SB623, used for the treatment of chronic cerebral infarction, traumatic brain injury, age-related macular degeneration, retinitis pigmentosa, Parkinson's disease, spinal cord injury and Alzheimer's disease; enhanced type-mesenchymal stem cells SB618, used to treat peripheral neuropathy, as well as muscle stem cells SB308, used in the treatment of muscular dystrophy.

SanBio Co (TSE:4592) Headlines

No Headlines